Merck Reports Positive Phase 2b/3 BRUNELLO Results for Remigromig
RAHWAY, N.J. — September 24, 2026 Merck announced topline results from the pivotal Phase 2b/3 BRUNELLO study evaluating remigromig...
BCVA
Advertisement
Octant Doses First Patient in Phase 1b/2 OCT-980 Study
EMERYVILLE, Calif. — September 24, 2026 Octant, Inc. announced that the first patient has been dosed in the Phase...
Annexon to Present Vonaprument Data From ARCHER II
BRISBANE, Calif. — September 24, 2026 Annexon, Inc. announced that it will present two oral presentations on vonaprument at...
BioAge Labs Begins Phase 2 Trial of Oral BGE-102
EMERYVILLE, California — September 8, 2026 BioAge Labs announced that the first participant has been dosed in the Phase...
Annexon Advances Vonaprument with Phase 2 Data
BRISBANE, Calif., July 14, 2026 Annexon announced that new analyses from its Phase 2 ARCHER trial evaluating vonaprument in...
Advertisements
ANI Reports Positive Phase 4 ILUVIEN Trial Results
PRINCETON, N.J., July 13, 2026 ANI Pharmaceuticals announced positive six-month topline results from the Phase 4, open-label, single-arm SYNCHRONICITY...
Advertisement
